Life Sciences Tools and Services
Company Overview of 4-Antibody AG
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. The company was founded in 2002 and is based in Basel, Switzerland. As of February 12, 2014, 4-Antibody AG operates as a subsidiary of Agenus Inc.
Founded in 2002
41 61 633 22 60
41 61 633 22 61
Key Executives for 4-Antibody AG
Similar Private Companies By Industry
|Andrew Alliance S.A.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact 4-Antibody AG, please visit www.agenusbio.com/contact/4-antibody.php. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.